keyword
MENU ▼
Read by QxMD icon Read
search

paliperidone

keyword
https://www.readbyqxmd.com/read/28096877/efficacy-and-safety-of-bitopertin-in-patients-with-schizophrenia-and-predominant-negative-symptoms-subgroup-analysis-of-japanese-patients-from-the-global-randomized-phase-2-trial
#1
Yoshio Hirayasu, Shin-Ichi Sato, Norifumi Shuto, Miwa Nakano, Teruhiko Higuchi
OBJECTIVE: The aim of the present study was to perform a subgroup analysis of data from a phase II global, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of bitopertin, a glycine reuptake inhibitor that activates N-methyl-D-aspartate receptors by increasing the concentration of glycine in the synaptic cleft, in Japanese and non-Japanese patients with schizophrenia and predominant negative symptoms. METHODS: Patients with schizophrenia and predominant negative symptoms on one or two antipsychotic drugs, including atypical antipsychotic drugs (olanzapine, risperidone, quetiapine, aripiprazole, and paliperidone) as the primary treatment, received bitopertin (10, 30, or 60 mg/day) or placebo once daily for 8 weeks as an add-on treatment...
January 2017: Psychiatry Investigation
https://www.readbyqxmd.com/read/28096874/prevalence-of-metabolic-syndrome-in-patients-with-schizophrenia-in-korea-a-multicenter-nationwide-cross-sectional-study
#2
Jung Sun Lee, Jun Soo Kwon, Daeho Kim, Sung-Wan Kim, Jae-Jin Kim, Jong-Hoon Kim, Hee Jung Nam, Seunghyong Ryu, Il Ho Park, Suk Kyoon An, Hong-Seok Oh, Seunghee Won, Kanguk Lee, Kyu Young Lee, Seung-Hwan Lee, Yu Sang Lee, Jung-Seo Yi, Kyung Sue Hong, Yeon Ho Joo
OBJECTIVE: We designed a nationwide study with limited exclusion criteria to investigate the prevalence of metabolic syndrome (MetS) in Korea and its relationship with antipsychotic medications. METHODS: This multicenter, cross-sectional, and observational study included patients diagnosed with schizophrenia or schizoaffective disorder. Sixteen hospitals enrolled 845 patients aged 18 to 65 years prescribed any antipsychotic medication between August 2011 and August 2013...
January 2017: Psychiatry Investigation
https://www.readbyqxmd.com/read/28062203/semi-mechanistic-computer-simulation-of-psychotic-symptoms-in-schizophrenia-with-a-model-of-a-humanized-cortico-striatal-thalamocortical-loop
#3
Athan Spiros, Patrick Roberts, Hugo Geerts
Despite new insights into the pathophysiology of schizophrenia and clinical trials with highly selective drugs, no new therapeutic breakthroughs have been identified. We present a semi-mechanistic Quantitative Systems Pharmacology (QSP) computer model of a biophysically realistic cortical-striatal-thalamo-cortical loop. The model incorporates the direct, indirect and hyperdirect pathway of the basal ganglia and CNS drug targets that modulate neuronal firing, based on preclinical data about their localization and coupling to voltage-gated ion channels...
January 3, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28055336/treatment-persistence-and-hospitalization-rates-among-patients-with-schizophrenia-a-quasi-experiment-to-evaluate-a-patient-information-program
#4
Dominic Pilon, Tony B Amos, Guillaume Germain, Marie-Hélène Lafeuille, Patrick Lefebvre, Carmela J Benson
OBJECTIVE: The effective treatment of schizophrenia requires continuous antipsychotic maintenance therapy. However, poor persistence of treatment is common among patients with schizophrenia. The objective of this study was to compare persistence and hospitalization rates among patients with schizophrenia treated with long-acting injectable (LAI) antipsychotics (i.e., paliperidone palmitate and risperidone) and enrolled in a patient information program (program cohort) with patients treated with oral antipsychotics (OAs) who were not enrolled in a patient information program (nonprogram cohort)...
January 5, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28054367/development-of-an-uplc-ms-ms-method-for-routine-therapeutic-drug-monitoring-of-aripiprazole-amisulpride-olanzapine-paliperidone-and-ziprasidone-with-a-discussion-of-their-therapeutic-reference-ranges-for-chinese-patients
#5
Shao-Ting Wang, Yan Li
A highly feasible and reliable ultra-high performance liquid chromatography tandem mass spectrometry method was presented for therapeutic drug monitoring of five anti-schizophrenic drugs (amisulpride, olanzapine, aripiprazole, paliperidone and ziprasidone) simultaneously. To meet the requirements of practical clinical usage (easy-handling, high-throughput and cost effective), the pretreatment process has been especially simplified (only including protein precipitation and mobile phase dilution steps) and the UPLC separation cycle was set within 6 minutes...
January 5, 2017: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/28049887/evaluation-of-the-expression-profile-of-extrapyramidal-symptoms-due-to-antipsychotics-by-data-mining-of-japanese-adverse-drug-event-report-jader-database
#6
Eiji Kose, Kana Uno, Hiroyuki Hayashi
 Typical antipsychotics are easily expressed as adverse events such as extrapyramidal symptom (EPS). On the other hand, incidence of adverse events due to atypical antipsychotics is low. Therefore, currently, atypical antipsychotics are widely used to treat schizophrenia. However, it has been reported that there is no difference in the frequency of EPS in atypical and typical antipsychotics. This study aimed to evaluate the expression profile of EPS in atypical and typical antipsychotics treatment using the Japanese Adverse Drug Event Report (JADER) database...
2017: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/28044942/emerging-pharmacological-therapies-in-schizophrenia-what-s-new-what-s-different-what-s-next
#7
Leslie Citrome
There are several new and emerging medication interventions for both the acute and maintenance treatment phases of schizophrenia. Recently approved are 2 new dopamine receptor partial agonists, brexpiprazole and cariprazine, as well as 2 new long-acting injectable antipsychotic formulations, aripiprazole lauroxil and 3-month paliperidone palmitate. Although differences in efficacy compared to other available choices are not expected, the new oral options offer different tolerability profiles that may be attractive for individual patients who have had difficulties with older medications...
December 2016: CNS Spectrums
https://www.readbyqxmd.com/read/28044455/health-care-resource-utilization-and-costs-of-california-medicaid-patients-with-schizophrenia-treated-with-paliperidone-palmitate-once-monthly-or-atypical-oral-antipsychotic-treatment
#8
Jacqueline A Pesa, Dilesh Doshi, Li Wang, Huseyin Yuce, Onur Baser
OBJECTIVE: To compare all-cause health care utilization and costs between patients with schizophrenia treated with once-monthly paliperidone palmitate (PP1M; Invega® Sustenna(®)) and atypical oral antipsychotic therapy (OAT). METHODS: This was a retrospective claims-based analysis among adult California Medicaid (Medi-Cal) patients with schizophrenia having ≥2 claims for PP1M or OAT from 01JUL2009-31DEC2013 and continuous health plan enrollment for ≥1 year pre- and post-index date (PP1M or OAT initiation date)...
January 3, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28039001/paliperidone-reverts-toll-like-receptor-3-signaling-pathway-activation-and-cognitive-deficits-in-a-maternal-immune-activation-mouse-model-of-schizophrenia
#9
Karina S MacDowell, Eva Munarriz-Cuezva, Javier R Caso, José L M Madrigal, Arantzazu Zabala, J Javier Meana, Borja García-Bueno, Juan C Leza
The pathophysiology of psychotic disorders is multifactorial, including alterations in the immune system caused by exogenous or endogenous factors. Epidemiological and experimental studies indicate that infections during the gestational period represent a risk factor to develop schizophrenia (SZ) along lifetime. Here, we tested the hypothesis that the antipsychotic paliperidone regulates immune-related brain effects in an experimental model of SZ. A well described prenatal immune activation model of SZ in mice by maternal injection of the viral mimetic poly(I:C) during pregnancy was used...
December 28, 2016: Neuropharmacology
https://www.readbyqxmd.com/read/28005578/paliperidone-palmitate-once-monthly-treatment-in-recent-onset-and-chronic-illness-patients-with-schizoaffective-disorder
#10
Cynthia A Bossie, Ibrahim Turkoz, Larry Alphs, Lucy Mahalchick, Dong-Jing Fu
Data from a multiphase schizoaffective disorder study (NCT01193153) were used to examine the effects of paliperidone palmitate once-monthly (PP1M) by subjects' illness duration, defined as recent onset (≤5 years since first psychiatric diagnosis; n = 206) and chronic illness (>5 years; n = 461). Symptom and functioning scores, as measured during open-label PP1M acute and stabilization treatment phases, improved in both subpopulations, with greater improvements in recent onset than chronic illness subjects (p ≤ 0...
December 21, 2016: Journal of Nervous and Mental Disease
https://www.readbyqxmd.com/read/28005435/is-there-a-weight-neutral-second-generation-antipsychotic-for-bipolar-disorder
#11
Fang Fang, Zuowei Wang, Renrong Wu, Joseph R Calabrese, Keming Gao
Antipsychotic-induced weight gain (WG) and metabolic abnormalities are major concerns. This review was untaken to answer if there is a weight-neutral second-generation antipsychotic for bipolar disorder (BPD). Areas covered: English-language literature in MEDLINE was searched with the keywords of antipsychotic/second-generation antipsychotic or generic/brand name of second-generation antipsychotic, and BPD/mania/depression or bipolar maintenance, and safety/tolerability or WG/weight increase, and randomized, placebo-controlled trial...
January 2, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28004623/new-ema-report-on-paliperidone-3-month-injections-taking-clinical-and-policy-decisions-without-an-adequate-evidence-base
#12
G Ostuzzi, D Papola, C Gastaldon, C Barbui
Three-month long-acting paliperidone is a new, recently marketed, formulation of paliperidone, characterised by the longest available dosing interval among long-acting antipsychotics. The clinical profile of 3-month long-acting paliperidone was recently summarised by the European Medicines Agency (EMA) in a public assessment report, released in April 2016. In this commentary, the main strengths and limitations of the EMA assessment report were appraised and discussed, in order to highlight possible implications for clinical practice, future research and regulatory practices for drug approval...
December 22, 2016: Epidemiology and Psychiatric Sciences
https://www.readbyqxmd.com/read/27994714/factors-associated-with-adherence-to-the-hedis-quality-measure-in-medicaid-patients-with-schizophrenia
#13
Marie-Hélène Lafeuille, Christian Frois, Michel Cloutier, Mei Sheng Duh, Patrick Lefebvre, Jacqueline Pesa, Zoe Clancy, John Fastenau, Mike Durkin
BACKGROUND: Treatment continuity is a major challenge in the long-term management of patients with schizophrenia; poor patient adherence to antipsychotic drugs has been associated with negative clinical outcomes. Long-acting injectable therapies may improve adherence and lessen the risk for psychiatric-related relapse, often leading to rehospitalization and higher healthcare costs. Therefore, understanding the determinants of adherence to antipsychotics is critical in the management of patients with schizophrenia...
October 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27971396/three-monthly-long-acting-formulation-of-paliperidone-palmitate-is-a-dominant-treatment-option-cost-saving-while-adding-qalys-compared-to-the-one-monthly-formulation-in-the-treatment-of-schizophrenia-in-belgium-a-cost-utility-study
#14
R De Moor, B Malfait, F Tedouri, C De Vos, C van Gils
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971385/outcomes-prediction-using-a-generalized-linear-model-in-a-cohort-of-schizophrenic-patients-receiving-paliperidone-long-acting-injectable-treatment-in-hong-kong
#15
W Y Choon, K K Lee, B C Wu, V W Lee, B Tomlinson, T Hu, W Chung, B S Lee
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970587/three-monthly-long-acting-formulation-of-paliperidone-palmitate-is-a-dominant-treatment-option-cost-saving-while-adding-qalys-compared-to-the-one-monthly-formulation-in-the-treatment-of-schizophrenia-in-france
#16
C Arteaga Duarte, X Colin, R De Moor, P Guillon, C W van Gils
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27938775/a-woman-in-her-60s-with-fever-and-altered-mental-status-in-a-psychiatric-hospital
#17
Benjamin C Kalivas, Andrew J Goodwin
A woman in her 60s with a history of hepatitis C with cirrhosis and major depressive disorder with psychotic features was admitted to the inpatient psychiatric unit for suicidal ideation. She was initially treated with a combination of sertraline and paliperidone. The paliperidone was subsequently changed to risperidone and ultimately to olanzapine. She developed worsening mental status and was then treated for catatonia with benzodiazepines. Over 2 days, her mental status continued to worsen and she developed fever and tachycardia...
December 2016: Chest
https://www.readbyqxmd.com/read/27931985/impact-of-regulatory-measures-on-antipsychotics-drug-consumption-in-castilla-y-le%C3%A3-n-spain
#18
L H Martín Arias, C Treceño Lobato, S Pérez García, P García Ortega, M Sáinz Gil, R Sanz Fadrique, A Carvajal García-Pando
OBJECTIVES: Antipsychotics are currently used to treat different diseases; even some off-labelled conditions are treated with this medication. Consumption and cost of antipsychotic drugs sharply increased in Spain after second-generation drugs were marketed; several regulatory measures were adopted to curb this trend. The aim of this study was to examine the impact of these measures upon the use and cost of antipsychotics. STUDY DESIGN: Study of drug use (SDU) from 1995 to 2012...
December 2016: Public Health
https://www.readbyqxmd.com/read/27928189/a-reasonable-alternative-to-clozapine-in-the-chronically-relapsing-smoking-patient-a-retrospective-analysis
#19
John R Tomko, Nadeem Ahmed, Cynthia Kuntz, Justine Zick
Background: Clozapine levels are severely decreased by cigarette smoke hydrocarbons. A new agent that is unaffected by smoking is paliperidone palmitate. Objective: The purpose of this study is to retrospectively evaluate hospital readmission and time until readmission for patients prescribed paliperidone palmitate intramuscular injection (PP) as an alternative to oral clozapine for patients with severe schizophrenia who resume smoking following discharge. A secondary analysis was performed to determine whether smoking status alone affects hospital readmission rates in both smoking and nonsmoking clozapine-treated patients...
November 2016: Hospital Pharmacy
https://www.readbyqxmd.com/read/27927736/multidimensional-assessment-of-functional-outcomes-in-schizophrenia-results-from-qualify-a-head-to-head-trial-of-aripiprazole-once-monthly-and-paliperidone-palmitate
#20
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Timothy Peters-Strickland, Maud Beillat, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Anna Eramo, Karina Hansen, Dieter Naber
BACKGROUND: QUALIFY was a 28-week, randomized, open-label, head-to-head trial that assessed improvements across multiple measures in stable patients with schizophrenia with aripiprazole once-monthly 400 mg vs paliperidone palmitate. METHODS: Secondary effectiveness assessments included physician-rated readiness for work using the Work Readiness Questionnaire, the Clinical Global Impression-Severity and Clinical Global Impression-Improvement scales, and quality of life with the rater-blinded Heinrichs-Carpenter Quality of Life Scale...
December 8, 2016: International Journal of Neuropsychopharmacology
keyword
keyword
32835
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"